

Minneapolis VA Health Care System
IBC (Institutional Biosafety Committee)

MEETING MINUTES

December 13, 2022

TEAMS

The meeting was called to order on December 13, 2022 at 5:00 PM and a quorum was present.

ATTENDANCE

Voting Members Present:

██████████	Community Member
██████████	Infectious Disease Physician
██████████	Attending Veterinarian
██████████	Chair
██████████	Community Member

Recording:

██████████	Staff
------------	-------

ITEMS

1 Welcome and Opening Remarks

2 Annual Reviews

2.1 [██████████] Orexin and serotonin interactions to promote physical activity and prevent obesity

PI:	Catherine Kotz
Reference Number:	██████████
Sponsor:	Department of Veterans Affairs
Submission Type:	Continuing Review/Progress Report
Review Type:	Full Committee Review
Action:	Approved
Effective Date:	December 13, 2022
Project Status:	Active
Vote:	Total = 5; For = 5; Opposed = 0; Abstained = 0;

Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols is noted.

2.2 [REDACTED] **Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis**

PI: Thomas Griffith, Ph.D.

Reference Number: [REDACTED]

Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review

Action: Approved

Effective Date: December 13, 2022

Project Status: Active

Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;

Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols is noted.

2.3 [REDACTED] **Combinatorial Targeting of the Cell Cycle and Key Interacting Pathways in Mesothelioma**

PI: Mark Klein

Reference Number: [REDACTED]

Sponsor: VA-ORD Biomedical Laboratory Research & Development

Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review

Action: Approved

Effective Date: December 13, 2022

Project Status: Active

Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;

Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols is noted.

2.4 [REDACTED] **Precision Oncology-Based Therapeutic Targeting in Mesothelioma**

PI: Mark Klein

Reference Number: [REDACTED]

Sponsor: Department of Defense
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: December 13, 2022
Project Status: Active
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols is noted.

2.5 [REDACTED] **Novel Plant Alkaloids for the Treatment of Obesity in Mice**

PI: Patricia Bunney
Reference Number: [REDACTED]
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: December 13, 2022
Project Status: Active
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols is noted.

3 **Closures**

3.1 [REDACTED] **Pharmacogenetic control of physical activity and food intake**

PI: Catherine Kotz
Reference Number: [REDACTED]
Submission Type: Closure/Final Report

Review Type: Full Committee Review
Action: Closed
Effective Date: December 13, 2022
Project Status: Closed
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

The objective of this project was to determine whether Orexin neuron activation enhances spontaneous physical activity (SPA), energy expenditure (EE), learning and memory; and reverses age-induced decline in SPA, EE and memory in mice. Orexin cre[±] mice were injected into the brain with an AAV-hM3Dq-mCherry vector to introduce DREDD (Designer Receptors Exclusively Activated Designer Drugs) into the area that can activate orexin expression upon injection of clozapine-n-oxide. We found that activation of LH orexin neurons increases SPA, memory and EE. In addition, orexin-activation reversed age induced reductions in SPA, EE, learning and memory in mice. The study is now closed - no hazards are in use and no samples are stored onsite.

4 Adjourn

The meeting adjourned on December 13, 2022 at 5:25 PM.

